Currently Viewing:
AMCP 2017
Analyzing the Near-Term Pipeline for Specialty Drugs
March 28, 2017
Dr Aimee Tharaldson Highlights Two Key Drugs for 2017
March 28, 2017
Effectively Moving Toward Value-Based Care
March 28, 2017
Susan A. Cantrell on the Evolution of Value Frameworks
March 28, 2017
Dr Liz Zhou Explains Basal Insulin Switching Study on Toujeo
March 28, 2017
Dr Richard Willke on Using Real-World Data to Inform Value-Based Contracts
March 29, 2017
The Unsustainably Big Business of Healthcare
March 29, 2017
Dr Matthew Pickering: How Quality Measures Are Created and Implemented
March 29, 2017
Addressing the Affordability Issue of Novel Treatments
March 29, 2017
Dr Clifford Goodman Outlines Takeaways From a Health Economic Case Study on Repatha
March 30, 2017
Dr Doug Hillblom on the State of e-Prescribing and Remaining Barriers
March 30, 2017
Cardiovascular Outcome Trials: How Misinterpretation of Statistics Can Affect Clinical Practice
March 30, 2017
Repatha Offers Additional LDL-C Reduction in a Convenient Dosage Form
March 30, 2017
ACA Repeal and Other Healthcare Issues on the Trump Administration's Agenda
April 03, 2017
The Latest in the Move to Value-Based Reimbursement and Remaining Challenges
April 04, 2017
Susan Cantrell: Uncertainty Is Affecting Everyone in Healthcare
April 11, 2017
Dr Aimee Tharaldson Discusses 2 New Treatments for Tardive Dyskinesia
April 12, 2017
Dr Gail Bridges Explains the High Real-World Cure Rate for HCV
April 17, 2017
Dr Richard Willke Previews ISPOR 2017 in Boston
April 18, 2017
Currently Reading
Dr Matthew Pickering Discusses Development, Implementation of Quality Measures
April 20, 2017
Dr Aimee Tharaldson: We're Keeping an Eye on Future NASH Treatments
April 27, 2017
Susan A. Cantrell Outlines Concerns and Opportunities for Managed Care
May 01, 2017
The Importance of Ethical Committees in the Evolving Healthcare Environment
May 11, 2017
Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements
May 17, 2017

Dr Matthew Pickering Discusses Development, Implementation of Quality Measures

The Pharmacy Quality Alliance (PQA) heavily relies on member organizations throughout the development and implementation of new quality measures, explained Matthew Pickering, PharmD, RPh, associate director of research and quality strategies at PQA.


The Pharmacy Quality Alliance (PQA) heavily relies on member organizations throughout the development and implementation of new quality measures, explained Matthew Pickering, PharmD, RPh, associate director of research and quality strategies at PQA.

Transcript

When the Pharmacy Quality Alliance is creating new measures, how does it work with its members?

PQA is a multistakeholder consensus-based entity and it was established in 2006 as a public-private partnership with CMS to develop quality measures to implement in the Medicare Part D benefit. And PQA has over 215 member organizations across a broad range of healthcare stakeholders. We actively engage our members throughout our measure development process. Including measurement generation.

Our development teams, our advisory groups, our technical expert panels consist of representatives across our broad member organizations. We rely heavily on their expertise and their insights. And it is very much instrumental for our measure development and implementation overall.

What is done to update or rotate out quality measures?

Measures endorsed under NQF, or the National Quality Forum, really have a review for an update every 3 years. And this update is intended to look at the performance of the measures to see if there is a gap that still exists. If the rates are still low or high depending on the measure specifications, then we may need to continue to implement that measure. Maybe there are guidelines that we need to change the eligible population or exclusions, such as certain age criteria, etc.

So those updates that's currently what goes on, and PQA does that, but in addition, we also update our national drug code lists, our NDCs. PQA obviously develops measures that are for medications and immunizations, and new medications come out quite frequently throughout the year. We need to update those drug code lists more frequently than every 3 years. So we do that every 6 months and we provide those new lists to the implementers who are actually using those measures.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!